FibroBiologics, Inc. (FBLG) - Dilution Analysis

8-K filing: FibroBiologics, Inc. has sold 71,830 shares of common stock under an At The Market Offering Agreement with H.C. Wainwright & Co., LLC, with the potential to sell up to $7,500,000 worth of shares.

10-Q filing | 5.2M shares outstanding

8-K filing: FibroBiologics, Inc. closed a public offering of common stock, pre-funded warrants, and warrants, generating net proceeds of approximately $2.5 million. ($1.36M proceeds)

8-K filing: Stock split 1-for-20 | Outstanding: 3,512,845 → 175,642

S-1 filing: FibroBiologics, Inc. is offering up to 1,136,363 shares of common stock together with warrants to purchase up to 1,136,363 shares of common stock, up to 1,136,363 pre-funded warrants to purchase common stock, and placement agent warrants to purchase up to 79,545 shares of common stock.

S-1 filing: This prospectus relates to the registration of the resale or other disposition, from time to time, of up to 22,494,434 shares of our common stock by the selling stockholders.

8-K filing: FibroBiologics, Inc. entered into a securities purchase agreement to issue and sell 5,227,275 shares of common stock at $0.33 per share in a registered direct offering, along with warrants to purchase an equal number of shares, with gross proceeds expected to be approximately $1.7 million. ($1.72M proceeds)

8-K filing: FibroBiologics, Inc. entered into a securities purchase agreement to sell 4,477,614 shares of common stock at $0.335 per share in a registered direct offering, and will issue warrants to purchase 4,477,614 shares of common stock in a concurrent private placement. ($3.0M proceeds)

8-K filing: FibroBiologics, Inc. enters into a securities purchase agreement for a registered direct offering of common stock and pre-funded warrants, along with a concurrent private placement of warrants, using sovereign-issued gold coins as payment. ($4.0M proceeds)

10-Q filing | 51.5M shares outstanding

8-K filing: FibroBiologics, Inc. issued a total of 2,154,530 shares of its common stock to YA II PN, Ltd. between June 20, 2025 and July 15, 2025, upon conversion of convertible promissory notes.

8-K filing: FibroBiologics, Inc. issued a $5 million convertible promissory note to YA II PN, Ltd. as the third tranche of a Standby Equity Purchase Agreement. Additionally, the Investor converted portions of the Second Note, resulting in the issuance of several tranches of common stock to the investor between January 23, 2025, and June 3, 2025. ($4.7M proceeds)

10-Q filing | 36.7M shares outstanding

10-K filing | 37.7M shares outstanding

8-K filing: FibroBiologics, Inc. issued shares of common stock to YA II PN, LTD. upon conversion of promissory notes. ($0.25M proceeds)

S-3 filing: FibroBiologics, Inc. may offer and sell from time to time our common stock, preferred stock, depositary shares, warrants, subscription rights, contingent value rights, debt securities and purchase contracts, as well as units that include any of these securities with an aggregate initial offering price of $50,000,000.

POS AM filing: Post-Effective Amendment No. 1 to the Registration Statement is being filed to terminate the effectiveness of the Registration Statement and to remove from registration all securities registered but not sold under the Registration Statement.

S-1/A filing: Registration of resale of common stock by YA II PN, LTD, and potential sales of common stock to Yorkville pursuant to a standby equity purchase agreement.

S-1 filing: The filing is an S-1 registration statement for the resale of common stock by YA II PN, LTD (Yorkville) and the potential sale of common stock to Yorkville pursuant to a standby equity purchase agreement (SEPA) for up to $25,000,000.

8-K filing: FibroBiologics, Inc. sold 1,152,074 shares of Common Stock to GEM at a price of $2.17 per share for an aggregate purchase price of $2.5 million on December 19, 2024. ($2.5M proceeds)

10-Q filing | 33.5M shares outstanding

8-K filing: FibroBiologics, Inc. sold 100,000 shares of common stock to GEM Global Yield LLC SCS at a net price of $4.51 per share, resulting in gross proceeds of $451,000. ($0.45M proceeds)

POS AM filing: Post-Effective Amendment No. 1 to the Registration Statement is being filed to terminate the effectiveness of the Registration Statement and to remove from registration all securities registered but not sold under the Registration Statement.

10-Q filing | 32.7M shares outstanding

S-1 filing: This S-1 filing registers shares of common stock that may be sold to GEM pursuant to the GEM SPA. The filing assumes a minimum purchase price of $6.06 per share.

S-1/A filing: FibroBiologics, Inc. is offering up to 1,742,160 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, with the warrants having an exercise price of $11.48 and exercisable for five years.

S-1/A filing: FibroBiologics, Inc. is offering up to 1,801,801 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, as well as up to 1,801,801 shares of common stock underlying the warrants.

10-Q filing | 31.1M shares outstanding

S-1 filing: FibroBiologics, Inc. is offering up to 1,801,801 units, each consisting of one share of common stock and one warrant to purchase one share of common stock.

S-1/A filing: This is an S-1/A filing. The company has commenced listing its common stock on Nasdaq as of January 31, 2024. They have issued shares of Series B and B-1 Preferred Stock in private placements and crowdfunded offerings. In February and March 2024, they issued common stock to GEM pursuant to a draw-down notice.

10-K filing | 32.6M shares outstanding

S-1/A filing: This is an S-1/A filing. The document discusses the issuance of Series B-1 Preferred Stock and warrants to purchase common stock in private placements.

S-1/A filing: The filing relates to the registration statement, exhibits, and financial statement schedules. It also mentions private placements of Series B-1 Preferred Stock and warrants to purchase common stock.

S-1/A filing: The Company shall deliver a warrant to Maxim to purchase shares of the Company's Common Stock equal to four percent (4.0%) of the number of shares of Common Stock underlying the securities issued in the Financing.

S-1/A filing: This is an S-1/A filing. The document discusses the issuance of Series B-1 Preferred Stock and warrants to purchase common stock in private placements and to investors who subscribed to purchase shares of Series B-1 Preferred Stock.

S-1/A filing: This S-1/A filing details the issuance of Series B-1 Preferred Stock and warrants to purchase common stock in private placements from April 2023 through November 2023.

S-1/A filing: This is an S-1/A filing. It details the issuance of Series B-1 Preferred Stock and warrants to purchase common stock in private placements and to investors.

S-1/A filing: This is an S-1/A filing related to the registration of Common Stock or other equity securities.

S-1/A filing: This is an S-1/A filing related to the registration of securities. It includes details of previously issued Series B-1 Preferred Stock and warrants.

S-1 filing: This is an S-1 filing for a potential offering. From April 2023 through September 2023, the company issued an aggregate of the equivalent of 74,922 shares of Series B-1 Preferred Stock to investors in a private placement, at prices ranging from $18.00 to $20.00 per share. They also agreed to issue warrants, exercisable for a period of three years, to purchase an aggregate of 8,890 shares of common stock at an exercise price of $20.00 per share.